Current Report · Items 2.02, 7.01, 9.01 · 8-K

ARS Pharmaceuticals, Inc.

SPRYNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Filed May 15, 2026Accepted May 15, 2026, 6:02 AM EDTCIK 1671858Accession 0001193125-26-225055

Company context

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and UK), an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children aged 4 years and older who weigh 15 kg or greater. For more information, visit www.ars-pharma.com and follow us on LinkedIn and X.

Current securities

SPRYNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 15, 2026, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter and year ended March 31, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 15, 2026, the Company updated its corporate presentation for use with investors, analysts and others. The revised presentation is available through the Company’s website, and a copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Filed exhibits (2)

EX-99.1 (by filename) spry-ex99_1.htm

EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million including neffy U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 15, 2026 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients against allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2026 and provided an update on the continued commercialization of neffy® (epinephrine nasal spray), the first and only FDA- and European Commission-approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis. “Building on strong commercial momentum, neffy is redefining the landscape f…

Open exhibit ↗

EX-99.2 (by filename) spry-ex99_2.htm

EX-99.2 3 spry-ex99_2.htm EX-99.2 May 2026 Corporate Presentation neffy - the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential market, demand and expansion opportunities for neffy; the belief that ARS Pharma is positioned to accelerate market share expansion; the anticipated gross-to-net percentage range; the expected intellectual property protection for neffy; guidance regarding ARS Pharma’s future performance and results of operations, including any cash or cash equivalent resource projections; the design and potential benefits of neffy, including its needle-free, compact, portable and easy to use design, reliability, temperature stability, and the likelihood allergy patients and caregivers will choose to carry and dose neffy compared to needle-bearing options; the belief that real-world outcomes data support the cl…

Open exhibit ↗